Hua Medicine announced that on October 9, 2022, the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company, has been officially approved by the National Medical Products Administration (NMPA) of China on October 8th, to be used as monotherapy for drug nanve Type 2 diabetes (T2D) patients or in combination with metformin in metformin tolerated T2D patients
to control blood glucose level. For those patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required.